NCT03448835Active, not recruitingPhase 2
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Non-metastatic, Resectable Gastric and GE-junction Cancer: The PANDA Trial
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment. The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 22 Nov 2017
- Start date
- 7 Mar 2018
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- The Netherlands Cancer Institute
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT03448835
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From 7 Mar 2018 to the primary completion date, 31 Oct 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- no major surgical procedure within 4 weeks prior to initiation of study treatment
- no current treatment with anti-viral therapy or HBV
Other illness
- no active or history of autoimmune disease or immune deficiency
- no significant cardiovascular disease
- no history of malignancy within 3 years prior to screening
Other
- no signs of distant metastases
- no pregnancy or breastfeeding
Who the study is looking for
- signed informed consent
- patients age 18 and older
- primary resectable, histologically confirmed gastric or GEJ adenocarcinoma
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Marieke van de Belt Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
| Catharina Ziekenhuis Coordinator of this site? Confirm its status | Eindhoven | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.